Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes of NexoBrid vs standard of care in pediatric burn patients
2022-001909-53Phase 3Completed
- Sponsor
- MediWound
- Start
- Jun 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of bromelain in burn injury (2 arms), sponsored by MediWound. Primary endpoints: Long-term cosmesis, Long-term function and 1 more. Started Jun 2022; status: completed.
02
Drugs
bromelain
03
Conditions
burn injury
Beyond the preview
Go deeper on 2022-001909-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001909-53.